BACKGROUND: Hip fracture is associated with high morbidity and mortality. Pelvic external beam radiotherapy (EBRT) is known to increase the risk of hip fractures in women, but the effect in men is unknown. METHODS: From the Surveillance, Epidemiology, and End Results (SEER)-Medicare database, 45,662 men who were aged ≥66 years and diagnosed with prostate cancer in 1992-2004 were identified. By using Kaplan-Meier methods and Cox proportional hazards models, the primary outcome of hip fracture risk was compared among men who received radical prostatectomy (RP), EBRT, EBRT plus androgen suppression therapy (AST), or AST alone. Age, osteoporosis, race, and other comorbidities were statistically controlled. A secondary outcome was distal forearm fracture as an indicator of the risk of fall-related fracture outside the radiation field. RESULTS: After covariates were statistically controlled, the findings showed that EBRT increased the risk of hip fractures by 76% (hazards ratio [HR], 1.76; 95% confidence interval [CI], 1.38-2.40) without increasing the risk of distal forearm fractures (HR, 0.80; 95% CI, 0.56-1.14). Combination therapy with EBRT plus AST increased the risk of hip fracture 145% relative to RP alone (HR, 2.45; 95% CI, 1.88-3.19) and by 40% relative to EBRT alone (HR, 1.40; 95% CI, 1.17-1.68). EBRT plus AST increased the risk of distal forearm fracture by 43% relative to RP alone (HR, 1.43; 95% CI, 0.97-2.10). The number needed to treat to result in 1 hip fracture during a 10-year period was 51 patients (95% CI, 31-103). CONCLUSIONS: In men with prostate cancer, pelvic 3-D conformal EBRT was associated with a 76% increased risk of hip fracture. This risk was slightly increased further by the addition of short-course AST to EBRT. This risk associated with EBRT must be site-specific as there was no increase in the risk of fall-related fractures in bones that were outside the radiation field.
BACKGROUND:Hip fracture is associated with high morbidity and mortality. Pelvic external beam radiotherapy (EBRT) is known to increase the risk of hip fractures in women, but the effect in men is unknown. METHODS: From the Surveillance, Epidemiology, and End Results (SEER)-Medicare database, 45,662 men who were aged ≥66 years and diagnosed with prostate cancer in 1992-2004 were identified. By using Kaplan-Meier methods and Cox proportional hazards models, the primary outcome of hip fracture risk was compared among men who received radical prostatectomy (RP), EBRT, EBRT plus androgen suppression therapy (AST), or AST alone. Age, osteoporosis, race, and other comorbidities were statistically controlled. A secondary outcome was distal forearm fracture as an indicator of the risk of fall-related fracture outside the radiation field. RESULTS: After covariates were statistically controlled, the findings showed that EBRT increased the risk of hip fractures by 76% (hazards ratio [HR], 1.76; 95% confidence interval [CI], 1.38-2.40) without increasing the risk of distal forearm fractures (HR, 0.80; 95% CI, 0.56-1.14). Combination therapy with EBRT plus AST increased the risk of hip fracture 145% relative to RP alone (HR, 2.45; 95% CI, 1.88-3.19) and by 40% relative to EBRT alone (HR, 1.40; 95% CI, 1.17-1.68). EBRT plus AST increased the risk of distal forearm fracture by 43% relative to RP alone (HR, 1.43; 95% CI, 0.97-2.10). The number needed to treat to result in 1 hip fracture during a 10-year period was 51 patients (95% CI, 31-103). CONCLUSIONS: In men with prostate cancer, pelvic 3-D conformal EBRT was associated with a 76% increased risk of hip fracture. This risk was slightly increased further by the addition of short-course AST to EBRT. This risk associated with EBRT must be site-specific as there was no increase in the risk of fall-related fractures in bones that were outside the radiation field.
Authors: J J Jacobs; L R Kull; G A Frey; S Gitelis; M B Sheinkop; T S Kramer; A G Rosenberg Journal: J Bone Joint Surg Am Date: 1995-12 Impact factor: 5.284
Authors: Michel Bolla; Laurence Collette; Léo Blank; Padraig Warde; Jean Bernard Dubois; René-Olivier Mirimanoff; Guy Storme; Jacques Bernier; Abraham Kuten; Cora Sternberg; Johan Mattelaer; José Lopez Torecilla; J Rafael Pfeffer; Carmel Lino Cutajar; Alfredo Zurlo; Marianne Pierart Journal: Lancet Date: 2002-07-13 Impact factor: 79.321
Authors: Arnold L Potosky; Joan L Warren; Elyn R Riedel; Carrie N Klabunde; Craig C Earle; Colin B Begg Journal: Med Care Date: 2002-08 Impact factor: 2.983
Authors: Megan M Pendleton; Shannon R Emerzian; Jennifer Liu; Simon Y Tang; Grace D O'Connell; Joshua S Alwood; Tony M Keaveny Journal: Bone Date: 2019-08-21 Impact factor: 4.398
Authors: Michael J Zelefsky; Marisa A Kollmeier; Elan Gorshein; Xin Pei; Marina Torres; Sean McBride; Laura Happersett; Gil'ad N Cohen; Yoshiya Yamada Journal: Radiother Oncol Date: 2016-10-15 Impact factor: 6.280
Authors: Megan E Oest; Connor G Policastro; Kenneth A Mann; Nicholas D Zimmerman; Timothy A Damron Journal: J Bone Miner Res Date: 2017-10-04 Impact factor: 6.741
Authors: Schroder Sattar; Shabbir M H Alibhai; Sandra L Spoelstra; Rouhi Fazelzad; Martine T E Puts Journal: Support Care Cancer Date: 2016-07-22 Impact factor: 3.603
Authors: Tisheeka R Graham-Steed; Pamela R Soulos; Natalie Dearing; John Concato; Mary E Tinetti; Cary P Gross Journal: J Geriatr Oncol Date: 2014-09-18 Impact factor: 3.599
Authors: Andrew M McDonald; Eddy S Yang; Kenneth G Saag; Emily B Levitan; Nicole C Wright; John B Fiveash; Soroush Rais-Bahrami; Smita Bhatia Journal: Arch Osteoporos Date: 2020-02-29 Impact factor: 2.617
Authors: Abhishek Chandra; Shenghui Lan; Ji Zhu; Tiao Lin; Xianrong Zhang; Valerie A Siclari; Allison R Altman; Keith A Cengel; X Sherry Liu; Ling Qin Journal: Bone Date: 2013-03-05 Impact factor: 4.398